New: Introducing the Finviz Futures Map

Madrigal Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Madrigal Pharmaceuticals, Inc.

Sep-04	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Sep-03	Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference MDGL GlobeNewswire
Aug-21	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Aug-19	Madrigal Receives European Commission Approval for Rezdiffra (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis MDGL GlobeNewswire
Aug-11	Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference MDGL GlobeNewswire
Aug-07	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Aug-05	Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates MDGL GlobeNewswire
Jul-30	Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited MDGL GlobeNewswire
Jul-25	Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 MDGL GlobeNewswire
Jul-22	Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH MDGL GlobeNewswire
Jul-16	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Jul-16	Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra (Resmetirom) MDGL GlobeNewswire
Jun-20	Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis MDGL GlobeNewswire
Jun-17	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) MDGL GlobeNewswire
Jun-02	Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference MDGL GlobeNewswire
May-10	Madrigal Announces New Clinical Data Demonstrating Rezdiffra (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis MDGL GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.